Skip to content

Study · Observational study · n = 60 · 2021

2 results

Comparing Quality of Life in Type 2 Diabetic Patients Using Dulaglutide and Liraglutide

Ghosh A

Journal of the Endocrine Society3 May 2021

PMCIDPMC8089580 (opens in a new tab)PepBankPUB-99072049
Read at sourceSource pageAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with diabetes, dulaglutide was linked to higher patient-centered quality-of-life scores than liraglutide.

    In plain wordsIn patients with diabetes, dulaglutide was linked to better quality-of-life scores than liraglutide.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePatient-centered quality of life
    Study

    n = 60

    Comparator
    Liraglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · at least six monthsAs given in this study (human).

    Measurements

    PCQoL
    66 score
    dulaglutide
    PCQoL
    56 score
    liraglutide

    Source sentences

    Summary
    The quality of life scores were better for dulaglutide than for liraglutide treated subjects (mean [SD] PCQoL: 66 [61–70] vs 56 [52 - 60], p < 0.05).
    3 context sentences
    Summary · context
    Sixty eligible patients on oral hypoglycaemic agents and Dulaglutide (N:30) or Liraglutide (N:30) formed the study group.
    Summary · context
    All study subjects were on steady dose of GLP 1 RA for at least six months before they took two part quality of life (general and diabetes related) questionnaire during their hospital visit.
    Summary · context
    Groups were matched for for age, sex, diabetes duration, comorbidities and HbA1C.
  2. 02HumanObservational studyEfficacy outcome

    In patients with diabetes, liraglutide was linked to lower patient-centered quality-of-life scores than dulaglutide.

    In plain wordsIn patients with diabetes, liraglutide was linked to lower quality-of-life scores than dulaglutide.

    Peptide
    Liraglutide
    Outcome
    DecreasePatient-centered quality of life
    Study

    n = 60

    Comparator
    Dulaglutide
    Outcome group
    Quality of life · Whole body
    Studied dose
    Dose not stated · at least six monthsAs given in this study (human).

    Measurements

    PCQoL
    56 score
    liraglutide
    PCQoL
    66 score
    dulaglutide

    Source sentences

    Summary
    The quality of life scores were better for dulaglutide than for liraglutide treated subjects (mean [SD] PCQoL: 66 [61–70] vs 56 [52 - 60], p < 0.05).
    3 context sentences
    Summary · context
    Sixty eligible patients on oral hypoglycaemic agents and Dulaglutide (N:30) or Liraglutide (N:30) formed the study group.
    Summary · context
    All study subjects were on steady dose of GLP 1 RA for at least six months before they took two part quality of life (general and diabetes related) questionnaire during their hospital visit.
    Summary · context
    Groups were matched for for age, sex, diabetes duration, comorbidities and HbA1C.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.